REDX.L Regulatory News (REDX)

AIM: REDX

 REDX PHARMA PLC

("Redx" or "the Company")

AGM Statement

Sixth proof of concept

Potential new treatment for gonorrhoea

Redx, the drug discovery and development company, will be holding its Annual General Meeting today and Chairman, Dr Frank Armstrong, will make the following comment on the Company's progress:

"Redx continues to make substantial progress across its research programs and we are delighted to announce today that we have reached the pre-clinical proof of concept stage with an anti-infective lead that has the potential to treat gonorrhoea, one of the most common sexually transmitted infections ("STI") globally, with over 106 million cases each year*. The need for a new treatment for this STI is becoming ever more urgent with resistance to last-line antibiotics now emerging as a critical problem.

This is the second proof of concept to have been delivered from our anti-infectives pipeline in the last 18 months. To date, six proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

Our drug development candidate in the Porcupine program, which has the potential to target hard-to-treat cancers including pancreatic, triple negative breast and head and neck cancers, continues to offer very exciting potential. Alongside our MRSA compound, we expect it to progress into first-in-human clinical trials in the first quarter of 2017.

We continue to view prospects for the business with confidence."

A presentation to be delivered to shareholders by Neil Murray, Chief Executive, at today's AGM will be available on the Company's website: redxpharma.com

* WHO Global Action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae (2012) http://apps.who.int/iris/bitstream/10665/44863/1/9789241503501_eng.pdf 

For further information, please contact:

About Redx Pharma Plc

www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary (patent‑protected) drug programs. Six proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

About Gonorrhoea

Gonorrhoea is a sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae. It is the second most commonly reported sexually transmitted infection in Europe and in England in 2014, almost 35,000 cases were reported, a 19% increase on the prior year.

Control of gonorrhea relies entirely on antibiotics and is currently being challenged by emerging resistance to third-generation cephalosporins. The last line of defence against Gonorrhoea is therefore being quickly depleted leading to a need for new antibiotics.